Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) disclosed that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Application for reproxalap, an investigational reactive aldehyde species trap, for the treatment of signs and symptoms of dry eye disease. The CRL indicates the FDA determined the application does not currently meet the requirements for approval, citing a lack of substantial evidence of efficacy from the submitted clinical program.
The FDA stated that the application "failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease." The agency noted that inconsistency across study results "raises serious concerns about the reliability and meaningfulness of the positive findings" and that the "totality of evidence from the completed clinical trials does not support the effectiveness of the product." No safety or manufacturing deficiencies were identified. The FDA recommended that Aldeyra explore reasons for trial failures and identify populations or conditions in which reproxalap may demonstrate efficacy. The agency did not recommend conducting additional clinical trials or request submission of additional confirmatory evidence.
Reproxalap is a small molecule that functions by covalently binding and sequestering toxic reactive aldehyde species, such as malondialdehyde and 4-hydroxynonenal, which are elevated in inflammatory conditions. This mechanism differs from existing dry eye treatments, which include calcineurin inhibitors such as cyclosporine, corticosteroids such as loteprednol etabonate, and nicotinic acetylcholine receptor agonists such as varenicline nasal spray. The dry eye disease treatment landscape includes several approved therapies — Miebo (perfluorohexyloctane), Tyrvaya (varenicline), Eysuvis (loteprednol etabonate), and Cequa (cyclosporine) — though the company has described reproxalap as, to its knowledge, the only drug with clinical activity within minutes of administration in this patient population.
Reproxalap originated from academic research into aldehyde-mediated inflammation and oxidative stress. Aldeyra Therapeutics was founded to translate this science into therapeutic applications and has retained full ownership and development rights throughout the program's history. No licensing, partnership, or asset transfer arrangements have been publicly disclosed for reproxalap. The company has funded development through public equity offerings and internal resources.